Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

Inclusion Criteria Patients must have: * Esophageal candidiasis. * Histological evidence of Candida spp. at baseline with confirmation by positive mycological culture. * HIV infection or other predisposing risk factor. * Life expectancy of at least 2 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Malignancies of the head or neck, if the treatment or disease will interfere with response assessment. * Evidence of systemic fungal infection. * Underlying clinical condition that would preclude study completion. * Judged to be unreliable in regard to following physician's directives. Concurrent Medication: Excluded: * Rifampin. * Rifabutin. * Phenobarbital. * Phenytoin. * Carbamazepine. * Terfenadine. * Astemizole. * H2 blockers. * Continual antacids. * Any investigational drug (expanded access drugs are allowed). Patients with the following prior conditions are excluded: * History of significant hepatic abnormalities or clinical evidence of hepatic disease within 2 months prior to study entry. * History of hypersensitivity to imidazole or azole compounds. Prior Medication: Excluded: * Other orally administered antifungal therapy within 3 days prior to study entry. * Any investigational drug within 1 month prior to study entry (expanded access drugs are allowed).